AstraZeneca, Merck Announce LYNPARZA S Met Primary Endpoint of Progression-Free Survival in Women with BRCA-Mutated Advanced Ovarian Cancer and Showed a Safety Profile Consistent with Previous Trials
Benzinga Newdesk